Abstract |
An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.
|
Authors | Kah-Whye Peng, Timothy Carey, Patrycja Lech, Rianna Vandergaast, Miguel Á Muñoz-Alía, Nandakumar Packiriswamy, Clement Gnanadurai, Karina Krotova, Mulu Tesfay, Christopher Ziegler, Michelle Haselton, Kara Sevola, Chase Lathrum, Samantha Reiter, Riya Narjari, Baskar Balakrishnan, Lukkana Suksanpaisan, Toshie Sakuma, Jordan Recker, Lianwen Zhang, Scott Waniger, Luke Russell, Christopher D Petro, Christos A Kyratsous, Alina Baum, Jody L Janecek, Rachael M Lee, Sabarinathan Ramachandran, Melanie L Graham, Stephen J Russell |
Journal | Vaccine
(Vaccine)
Vol. 40
Issue 15
Pg. 2342-2351
(04 01 2022)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 35282925
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021. Published by Elsevier Ltd. |
Chemical References |
- Antibodies, Neutralizing
- Antibodies, Viral
- Lipid Nanoparticles
- Liposomes
- Spike Glycoprotein, Coronavirus
- Viral Vaccines
- spike protein, SARS-CoV-2
|
Topics |
- Animals
- Antibodies, Neutralizing
- Antibodies, Viral
- COVID-19
(prevention & control)
- Liposomes
- Nanoparticles
- Primates
- Rhabdoviridae
- SARS-CoV-2
- Spike Glycoprotein, Coronavirus
(genetics)
- Viral Vaccines
|